Entrada Therapeutics, Inc.

TRDA

Find Out if You Qualify for a Financial Reward by filling out the form below.

Entrada Therapeutics, Inc. Form












Class Action Lawsuit List does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

After the market closed on December 19, 2022, Entrada issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) had placed a clinical hold on the Company’s Investigational New Drug Application for ENTR-601-44 (a drug for the potential treatment of Duchenne muscular dystrophy). The FDA indicated that they would provide an official Clinical Hold letter to Entrada within 30 days. On this news, Entrada’s stock price fell 19.76%, to close at $15.96 per share on December 20, 2022. Then, on November 22, 2023, Entrada announced that, after reevaluating additional information on ENTR-601-44, the FDA refused to lift the previously announced clinical hold on its Phase 1 trial.

On this news, Entrada’s stock price fell over 31%, to close at $11.36 per share on November 22, 2023.

Active Cases

Ticker Symbol Company Name Join Deadline Join
EW Edwards Lifesciences Corporation December 13, 2024 Join
TD The Toronto-Dominion Bank December 23, 2024 Join
WOLF Wolfspeed, Inc. January 17, 2025 Join